Compare MCFT & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MCFT | CERS |
|---|---|---|
| Founded | 1968 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | EDP Services |
| Sector | Industrials | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 326.9M | 276.0M |
| IPO Year | 2015 | 1997 |
| Metric | MCFT | CERS |
|---|---|---|
| Price | $18.99 | $1.89 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $22.20 | $4.00 |
| AVG Volume (30 Days) | 122.5K | ★ 1.4M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | ★ $287,846,000.00 | $199,191,000.00 |
| Revenue This Year | $9.21 | $25.31 |
| Revenue Next Year | $8.78 | $9.50 |
| P/E Ratio | $22.67 | ★ N/A |
| Revenue Growth | N/A | ★ 13.03 |
| 52 Week Low | $14.39 | $1.12 |
| 52 Week High | $23.94 | $2.24 |
| Indicator | MCFT | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 50.82 | 58.88 |
| Support Level | $18.00 | $1.81 |
| Resistance Level | $18.71 | $2.14 |
| Average True Range (ATR) | 0.62 | 0.13 |
| MACD | 0.16 | 0.01 |
| Stochastic Oscillator | 86.96 | 62.70 |
MasterCraft Boat Holdings Inc designs, manufactures, and markets performance sport boats and outboard boats. The company is based in the United States and operates in three brand-specific segments. The MasterCraft segment generates the majority of the company's revenue and includes inboard boats for water skiing, wakeboarding, and wake surfing. The Pontoon segment produces pontoon boats at its Owosso, Michigan facility. Pontoon boats are used for general recreational boating. The Aviara segment produces luxury day boats at its Merritt Island, Florida facility. Aviara boats are used for general recreational boating.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.